RPG Life Sciences Limited announces an acquisition

The reported cash consideration for the Actis Generics acquisition was Rs 80 Crores ^[1].

RPG Life Sciences’ latest reported consolidated cash and cash equivalents were Rs 150.46 Crores for Q1 FY27 ^[2]. The Actis transaction was announced in late July 2026 ^[1], after the June 30, 2026 quarter-end; therefore, the Rs 80 Crore payment is not reflected in that quarterly cash balance.

Pro forma cash impact:

• Reported consolidated cash: Rs 150.46 Crores ^[2]
• Less: Actis acquisition consideration: Rs 80 Crores ^[1]
• Pro forma cash, before other intervening cash movements: approximately Rs 70.46 Crores — derived from Rs 150.46 Crores less Rs 80 Crores.
• The payment represents approximately 53.17% of the reported cash balance — derived from Rs 80 Crores divided by Rs 150.46 Crores.

Thus, the acquisition would materially reduce liquidity, but the reported quarterly filing still showed Rs 150.46 Crores because the transaction occurred after the quarter-end. The Rs 70.46 Crore figure is a simple pro forma estimate, not the company’s reported post-acquisition cash balance.

Actis Generics’ revenue and EBITDA contribution were not separately disclosed. The reported Rs 80 Crores refers to the acquisition consideration for 100% of Actis, not to its revenue or EBITDA ^[3]. The completion filing confirms that Actis became a subsidiary on 24 September 2026, but does not provide target-level operating metrics ^[4].

Pre-acquisition revenue mix

†Assumes API and Formulations comprise the relevant two revenue buckets.

Mix implication: Actis is an API manufacturing business, so its post-acquisition revenue should increase the API share and reduce the Formulations share of RPG Life Sciences’ consolidated revenue. However, the size of the shift cannot be calculated because Actis revenue was not disclosed. On a full-period pro forma basis, the API share would be:

`(Rs 95.06 Crores + Actis revenue) / (Rs 707.52 Crores + Actis revenue)`

Accordingly, the defensible conclusion is:

• Actis revenue contribution: Not separately reported.
• Actis EBITDA contribution: Not separately reported; no EBITDA margin or profit bridge is available.
• Revenue mix: API moves above the pre-deal 13.44% baseline, while Formulations moves below the implied 86.56%, but the magnitude remains unquantifiable.
• Timing: FY26 reported mix is pre-acquisition, since the acquisition closed only on 24 September 2026 ^{[3] [4]}.

Verdict: An apples-to-apples EBITDA-margin comparison is not possible. Actis Generics’ historical revenue and EBITDA are not reported in the acquisition disclosures, while RPG Life Sciences has not separately disclosed EBITDA margins for its API segment. RPG’s reported standalone EBITDA margin was 26.40% in FY25, 24.40% in FY26 and 24.40% in Q1 FY27—but these are company-wide margins, not API margins. ^[5]

What appears to provide immediate operating adjacency

• The clearest near-term asset is manufacturing capability and backward integration, rather than a disclosed regulatory pipeline. Subsequent reporting describes Actis as operating close to full utilisation, which indicates an existing operating asset rather than merely a planned facility. ^[8]
• The 300 KL facility, 22 commercialised products and international approvals reported in the broader API expansion relate to the subsequent Raghava Life Sciences acquisition, not to Actis. They should not be attributed to Actis. ^[8]
• The Actis transaction therefore appears strategically synergistic through a dedicated API platform, manufacturing footprint and potential cross-utilisation of RPG’s customer, technical and procurement capabilities. However, no quantified cost savings, capacity number, product overlap or immediate EBITDA uplift has been disclosed. ^[6]

Bottom line: Actis offers identifiable manufacturing-platform and backward-integration optionality, but the evidence does not support a margin-accretion claim or a dossier-driven synergy case. The key diligence gap is Actis’s standalone financial history and a product-level schedule showing capacities, regulatory status, customers and overlap with RPG’s existing API portfolio.

_Scope note: this comparison also included Novartis India (NOVARTIND); Zota Health Care Limited (ZOTA); SMS Pharmaceuticals Limited (SMSPHARMA); Gujarat Themis Biosyn Ltd. (GUJTHEM); Orchid Pharma Limited (ORCHPHARMA), which the answer above does not cover. Ask about any of them for a full side-by-side._